InsiderTrades.com logo
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
From GoldenCrest Metals   |   Ad
The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.
Learn More Now
Christopher B. Prentiss net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Christopher Prentiss Biography and Net Worth

CFO of Adamas Pharmaceuticals
Chris joined the company in April 2015 as VP, Finance and Controller before becoming the Chief Accounting Officer of Adamas in September 2017. Before coming to Adamas, he was most recently VP, Finance and Controller at InterMune, Inc., a biotechnology company, until its acquisition by Roche. Prior to that, Chris was the Controller at Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, and held the same position at MannKind Corporation, a biotechnology company, as well as a variety of other finance roles. Prior to joining MannKind, Chris was a Senior Manager at KPMG LLP in the assurance practice. Chris received a Bachelor of Science degree in Accounting from Loyola Marymount University, and a Masters of Business Administration from Indiana University. Chris is a CPA licensed in California.

What is Christopher B. Prentiss' net worth?

The estimated net worth of Christopher B. Prentiss is at least $1.19 million as of March 22nd, 2021. Mr. Prentiss owns 145,017 shares of Adamas Pharmaceuticals stock worth more than $1,192,040 as of April 18th. This net worth approximation does not reflect any other assets that Mr. Prentiss may own. Learn More about Christopher B. Prentiss' net worth.

How do I contact Christopher B. Prentiss?

The corporate mailing address for Mr. Prentiss and other Adamas Pharmaceuticals executives is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. Adamas Pharmaceuticals can also be reached via phone at (510) 450-3500 and via email at [email protected]. Learn More on Christopher B. Prentiss' contact information.

Has Christopher B. Prentiss been buying or selling shares of Adamas Pharmaceuticals?

Christopher B. Prentiss has not been actively trading shares of Adamas Pharmaceuticals within the last three months. Most recently, Christopher B. Prentiss sold 2,422 shares of the business's stock in a transaction on Monday, March 22nd. The shares were sold at an average price of $5.48, for a transaction totalling $13,272.56. Following the completion of the sale, the chief financial officer now directly owns 145,017 shares of the company's stock, valued at $794,693.16. Learn More on Christopher B. Prentiss' trading history.

Who are Adamas Pharmaceuticals' active insiders?

Adamas Pharmaceuticals' insider roster includes Martha Demski (Director), Spyridon Papapetropoulos (Director), Christopher Prentiss (CFO), and Vijay Shreedhar (Insider). Learn More on Adamas Pharmaceuticals' active insiders.

Christopher B. Prentiss Insider Trading History at Adamas Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/22/2021Sell2,422$5.48$13,272.56145,017View SEC Filing Icon  
2/1/2021Sell3,821$6.36$24,301.5672,439View SEC Filing Icon  
1/20/2021Sell2,630$4.41$11,598.3076,260View SEC Filing Icon  
11/2/2020Sell2,050$3.21$6,580.5078,890View SEC Filing Icon  
1/21/2020Sell1,269$5.92$7,512.4870,940View SEC Filing Icon  
7/22/2019Sell1,082$6.00$6,492.0047,209View SEC Filing Icon  
3/20/2019Sell1,185$8.00$9,480.0031,612View SEC Filing Icon  
12/20/2018Sell228$7.51$1,712.28View SEC Filing Icon  
3/21/2018Sell567$25.98$14,730.6617,758View SEC Filing Icon  
See Full Table

Christopher B. Prentiss Buying and Selling Activity at Adamas Pharmaceuticals

This chart shows Christopher B Prentiss's buying and selling at Adamas Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Adamas Pharmaceuticals Company Overview

Adamas Pharmaceuticals logo
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
Read More

Today's Range

Now: $8.22
Low: $8.22
High: $8.22

50 Day Range

MA: $8.17
Low: $7.97
High: $8.23

2 Week Range

Now: $8.22
Low: $4.02
High: $9.15

Volume

N/A

Average Volume

692,487 shs

Market Capitalization

$376.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.82
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
From GoldenCrest Metals   |   Ad
The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.
Learn More Now